SLC5A2 and heart failure: According to various thresholds of left ventricular ejection fraction (40, 45, or 50%) used in the diagnosis of HFpEF, the subgroup analysis revealed that when using a left ventricular ejection fraction > 50% as the cut-off point for HFpEF, SGLT2 inhibitors also significantly reduced the composite endpoint of the first hospitalization for heart failure or cardiovascular death in patients with HFpEF (HR: 0.78, 95% CI: [0.68, 0.90], P = 0.0006, I2 = 22%) (as shown in Figure 4).